Dimana Miteva

592 total citations
27 papers, 169 citations indexed

About

Dimana Miteva is a scholar working on Hematology, Genetics and Physiology. According to data from OpenAlex, Dimana Miteva has authored 27 papers receiving a total of 169 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 26 papers in Genetics and 5 papers in Physiology. Recurrent topics in Dimana Miteva's work include Hemoglobinopathies and Related Disorders (22 papers), Acute Myeloid Leukemia Research (14 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Dimana Miteva is often cited by papers focused on Hemoglobinopathies and Related Disorders (22 papers), Acute Myeloid Leukemia Research (14 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Dimana Miteva collaborates with scholars based in United States, Italy and Switzerland. Dimana Miteva's co-authors include Olivier Hermine, Maria Domenica Cappellini, John B. Porter, Alì Taher, Ersi Voskaridou, Tatiana Zinger, Maciej Garbowski, Raffaella Origa, Jean‐Antoine Ribeil and Gian Luca Forni and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

Dimana Miteva

23 papers receiving 164 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dimana Miteva United States	7	134	124	41	24	19	27	169
Tatiana Zinger Lebanon	6	88 0.7×	74 0.6×	30 0.7×	18 0.8×	17 0.9×	7	112
J Arlet France	4	82 0.6×	61 0.5×	26 0.6×	24 1.0×	17 0.9×	14	123
Precious Pearl Landburg Netherlands	5	108 0.8×	75 0.6×	39 1.0×	35 1.5×	15 0.8×	8	149
Dominique Steschenko France	5	80 0.6×	73 0.6×	31 0.8×	56 2.3×	17 0.9×	10	161
R. Parra Spain	12	61 0.5×	273 2.2×	28 0.7×	43 1.8×	7 0.4×	21	299
Janine Collins United Kingdom	6	37 0.3×	97 0.8×	13 0.3×	22 0.9×	14 0.7×	13	131
Paraskevi Rea Oikonomidou United States	4	182 1.4×	167 1.3×	54 1.3×	25 1.0×	4 0.2×	6	211
Sadaf Pakdaman France	8	149 1.1×	168 1.4×	110 2.7×	23 1.0×	5 0.3×	14	222
Maria Letícia Ribeiro Portugal	9	120 0.9×	106 0.9×	42 1.0×	35 1.5×	15 0.8×	18	234
Merih Kızıl Çakar Türkiye	7	32 0.2×	67 0.5×	19 0.5×	15 0.6×	10 0.5×	40	125

Countries citing papers authored by Dimana Miteva

Since Specialization

Citations

This map shows the geographic impact of Dimana Miteva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dimana Miteva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dimana Miteva more than expected).

Fields of papers citing papers by Dimana Miteva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dimana Miteva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dimana Miteva. The network helps show where Dimana Miteva may publish in the future.

Co-authorship network of co-authors of Dimana Miteva

This figure shows the co-authorship network connecting the top 25 collaborators of Dimana Miteva. A scholar is included among the top collaborators of Dimana Miteva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dimana Miteva. Dimana Miteva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garcia‐Manero, Guillermo, Valeria Santini, Amer M. Zeidan, et al.. (2025). Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial. Advances in Therapy. 42(7). 3576–3589. 1 indexed citations

Yücel, Aylin, RK Goyal, Rohan Parikh, et al.. (2024). Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe. Future Oncology. 20(27). 1993–2004.

Olíva, Esther Natalie, Uwe Platzbecker, Matteo Giovanni Della Porta, et al.. (2024). Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study. Blood. 144(Supplement 1). 3216–3216. 2 indexed citations

Garcia‐Manero, Guillermo, Valeria Santini, Amer M. Zeidan, et al.. (2024). Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent-Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS Trial. Blood. 144(Supplement 1). 350–350. 1 indexed citations

Garcia‐Manero, Guillermo, Matteo Della Porta, Valeria Santini, et al.. (2024). Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS Trial. Blood. 144(Supplement 1). 1832–1832. 1 indexed citations

Platzbecker, Uwe, Valeria Santini, Rami S. Komrokji, et al.. (2023). Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts. Leukemia. 37(11). 2314–2318. 7 indexed citations

Taher, Alì, Khaled M. Musallam, Vip Viprakasit, et al.. (2023). Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia. BMJ Open. 13(3). e066683–e066683. 4 indexed citations

Cappellini, Maria Domenica, Alì Taher, Antonio Piga, et al.. (2023). Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept. European Journal Of Haematology. 111(1). 113–124. 6 indexed citations

Santini, Valeria, Rami S. Komrokji, Guillermo Garcia‐Manero, et al.. (2023). Long-Term Evaluation of Luspatercept in Erythropoiesis-Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study. Blood. 142(Supplement 1). 915–915. 1 indexed citations

10.

Germing, Ulrich, Pierre Fenaux, Uwe Platzbecker, et al.. (2023). Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study. Annals of Hematology. 102(2). 311–321. 4 indexed citations

11.

Olíva, Esther Natalie, Uwe Platzbecker, Matteo Giovanni Della Porta, et al.. (2023). Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naïve, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study. Blood. 142(Supplement 1). 4596–4596.

12.

Platzbecker, Uwe, Valeria Santini, Rami S. Komrokji, et al.. (2022). Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept in the MEDALIST Study. Blood. 140(Supplement 1). 9808–9810. 1 indexed citations

13.

Platzbecker, Uwe, Valeria Santini, Rami S. Komrokji, et al.. (2022). Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study. Blood. 140(Supplement 1). 6971–6973.

14.

Kattamis, Antonis, Vip Viprakasit, Maria Domenica Cappellini, et al.. (2021). Luspatercept Improves Quality of Life and Reduces Red Blood Cell Transfusion Burden in Patients with Non-Transfusion-Dependent β-Thalassemia in the BEYOND Trial. Blood. 138(Supplement 1). 3081–3081. 3 indexed citations

15.

Platzbecker, Uwe, Valeria Santini, Rami S. Komrokji, et al.. (2021). Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST Study. Blood. 138(Supplement 1). 1524–1524. 3 indexed citations

16.

Cappellini, Maria Domenica, Alì Taher, Antonio Piga, et al.. (2020). Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial. Blood. 136(Supplement 1). 8–9. 9 indexed citations

17.

Porter, John B., Maria Domenica Cappellini, Thomas D. Coates, et al.. (2019). Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial. Blood. 134(Supplement_1). 2245–2245. 8 indexed citations

18.

Viprakasit, Vip, Alì Taher, Olivier Hermine, et al.. (2019). Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions. Blood. 134(Supplement_1). 3545–3545. 2 indexed citations

19.

Cappellini, Maria Domenica, John B. Porter, Raffaella Origa, et al.. (2018). Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study. Haematologica. 104(3). 477–484. 68 indexed citations

20.

Cappellini, Maria Domenica, John B. Porter, Raffaella Origa, et al.. (2013). A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (β)-Thalassemia: Interim Results. Blood. 122(21). 3448–3448. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact